Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Retatrutide
LY3437943, Eli Lilly Triple Agonist
A GLP-1 receptor agonist originally developed for type 2 diabetes, now widely prescribed for weight management. One of the most commercially successful peptide drugs in history.
An investigational triple-agonist peptide developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials are underway, with early results showing unprecedented weight loss efficacy.
Mimics the incretin hormone GLP-1, stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system signaling. The result is improved blood sugar control and significant weight loss.
Activates three metabolic hormone receptors: GLP-1 (appetite suppression, insulin secretion), GIP (enhanced insulin response, fat metabolism), and glucagon (increased energy expenditure, fat oxidation). The triple mechanism may produce greater weight loss than dual agonists.
- Weight management
- Type 2 diabetes treatment
- Blood sugar regulation
- Cardiovascular risk reduction
- Weight management (investigational)
- Type 2 diabetes (investigational)
- Metabolic syndrome (investigational)
- Nausea and vomiting (common, usually transient)
- Pancreatitis (rare but serious)
- Gallbladder issues
- Potential thyroid tumor risk (animal studies)
- Muscle mass loss alongside fat loss
- GI side effects (diarrhea, constipation)
- Still in clinical trials — full safety profile unknown
- GI side effects (nausea, diarrhea, vomiting) reported in trials
- Not yet approved for any indication
- Long-term effects unknown
FDA-approved as Ozempic (diabetes, 2017), Wegovy (weight management, 2021), and Rybelsus (oral, diabetes, 2019). Multiple dosage forms and indications approved.
Currently in Phase 3 clinical trials. Phase 2 results showed up to 24% body weight loss at 48 weeks. FDA approval timeline uncertain but potentially 2027-2028.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.